Are Markers of Cardiac Dysfunction Useful in the Assessment of Cardiovascular Risk in Dialysis Patients?

Title:Are Markers of Cardiac Dysfunction Useful in the Assessment of Cardiovascular Risk in Dialysis Patients?

Volume: 23 Issue: 20

Author(s): Beata Franczyk, Anna Gluba-Brzózka*, Piotr Bartnicki, Maciej Banach and Jacek Rysz

Affiliation:

• Department of Nephrology, Hypertension and Family Medicine, WAM Teaching Hospital, Lodz, Poland, Zeromskiego 113, 90-549 Lodz,Poland

Keywords: Cardiac dysfunction, hemodialysis, ventricular arrhythmias, biomarkers, copeptin, GDF-15, HFABP.

Abstract: Background: Cardiovascular morbidity and mortality of dialysis patients are major problems in this group of patients.

Methods: The purpose of this study was also to evaluate whether any of the studied markers are better than troponin in early detection of the occurrence of ventricular arrhythmias and prolongation of QT interval. This study included 45 patients undergoing hemodialysis. ECG Holter and echocardiographic examination were performed before and after dialysis. The concentrations of markers: copeptin, GDF-15, HFABP and troponin were measured with the use of ELISA tests.

Results: We observed significantly higher QT (p=0.004), QTc (0.018), right atrium volume (p=0.006) and concentrations of copeptin (p<0.0001) and H-FABP (p<0.0001) as well as smaller left atrium volume (p<0.0001) and width of inferior vena cava (p<0.0001) after dialysis than before it. Significantly longer QT and higher copeptin levels were seen in patients with ventricular arrhythmia. A trend between the increase in copeptin concentration and H-FABP level and the presence of ventricular arrhythmias was also noted.

Conclusion: Generally, we failed to find any strong predictor of post-dialysis ventricular arrhythmia or the prolongation of QT, however, it seems that copeptin may have prognostic value, but this has to be analyzed in large studies.

Cite this article as:

Franczyk Beata , Gluba-Brzózka Anna *, Bartnicki Piotr , Banach Maciej and Rysz Jacek , Are Markers of Cardiac Dysfunction Useful in the Assessment of Cardiovascular Risk in Dialysis Patients?, Current Pharmaceutical Design 2017; 23 (20) . https://dx.doi.org/10.2174/1381612823666170508152501

DOI https://dx.doi.org/10.2174/1381612823666170508152501	Print ISSN 1381-6128
Publisher Name Bentham Science Publisher	Online ISSN 1873-4286